Close Menu

NEW YORK – Clinical genetics firm Blueprint Genetics and rare disease diagnostics company Archimedlife Medical Laboratory said today that they have partnered to offer biochemical testing for rare diseases in North America.

Under the agreement, Blueprint Genetics is licensing Archimedlife's technology and tests to offer biochemical testing at its Seattle laboratory, which also provides next-gen sequencing-based genetic testing. The combined testing services will be available in early 2020.

Financial terms and other details of the partnership were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.